All In Biotech

Drug Trial Radar · NCT07562178

Pemafibrate for Symptomatic ICAS RCT

Triglyceride-lowering Therapy With Pemafibrate for Prevention of Atherosclerotic Cardiovascular Disease in Patients With Symptomatic Intracranial Artery Stenosis: a Multi-center, Open-label, Randomized Controlled Trial (PPAR-ICAS)

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 270 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

270

Planned (sponsor's estimate)

Start

May 26, 2026

Primary completion

Mar 31, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Tokyo Women's Medical UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Kowa Company, Ltd.
First posted
May 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn whether pemafibrate can help prevent worsening of intracranial arterial stenosis (ICAS) in patients who have symptomatic ICAS and high triglycerides (TG) levels after ischemic stroke or transient ischemic attack (TIA). The main questions this study aims to answer are: 1. Does pemafibrate lower the chance that ICAS gets worse over 12 months? 2. Does pemafibrate improve TG levels and other vascular risk markers? 3. What are the effects of pemafibrate on vascular events, functional outcomes, and safety over 12 months? Researchers will compare a pemafibrate group with a non-pemafibrate group to see whether pemafibrate helps prevent progression of ICAS. This is an open-label, randomized, parallel-group trial. That means participants are assigned by chance to 1 of 2 groups, and both the researchers and participants know which group was assigned. Participants in both groups will continue to receive standard stroke care, including antithrombotic therapy and management of vascular risk factors such as blood pressure, low-density lipoprotein cholesterol, diabetes, and smoking. Participants may be eligible if they are 18 years or older, have clinically stable ischemic stroke or TIA, have 50% to 99% stenosis in a symptomatic intracranial artery on contrast-enhanced CT angiography (CTA), and have elevated fasting (\>=150 mg/dL) or non-fasting (\>=175 mg/dL) TG levels. Some people will not be eligible, such as those with ICAS due to non-atherosclerotic arterial disease, severe extracranial carotid stenosis, recent intravenous thrombolysis or mechanical thrombectomy, planned revascularization, contraindications to pemafibrate or iodinated contrast media, dialysis, or pregnancy. Participants will: * Be randomly assigned to a pemafibrate group or a non-pemafibrate group * Take pemafibrate for 12 months if assigned to the pemafibrate group, with possible dose adjustment based on TG levels and kidney function * Have blood tests and clinical assessments at baseline and during follow-up * Undergo brain CTA at study entry and again at 12 months * Undergo brain MRI/MRA and vascular tests such as ankle brachial index, cardio ankle vascular index, and pulse wave velocity according to the study schedule * Be followed for vascular events, functional outcome, and adverse events for 1 year

Conditions

  • Intracranial Atherosclerotic Disease (ICAD)
  • Hypertriglyceridaemia
  • Stroke (CVA) or TIA

Interventions

  • PemafibrateDrug

    Participants in this arm will receive pemafibrate in addition to standard medical therapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression in intracranial arterial stenosis on CTA at 12 months from enrollment (progression vs. no progression [no change or improvement])Time frame: Baseline and 12 months

Locations

42 sites in 1 country. Site status is shown where the registry gives one.

  • Fujita Health University Hospital

    Toyoake, Aichi-ken, Japan · Recruiting

  • Tokyo Women's Medical University Yachiyo Medical Center

    Yachiyo, Chiba, Japan · Recruiting

  • University of Fukui Hospital

    Yoshida, Fukui, Japan · Not yet recruiting

  • Brain Attack Center Ota Memorial Hospital

    Fukuyama, Hiroshima, Japan · Recruiting

  • Hiroshima City Hiroshima Citizens Hospital

    Hiroshima, Hiroshima, Japan · Recruiting

  • Kobe City Medical Center General Hospital

    Kobe, Hyōgo, Japan · Recruiting

  • University of Tsukuba Hospital

    Tsukuba, Ibaraki, Japan · Recruiting

  • Iwate Medical University Hospital

    Hizume, Iwate, Japan · Recruiting

  • Kagoshima City Hospital

    Kagoshima, Kagoshima-ken, Japan · Not yet recruiting

  • Kagoshima Medical Center

    Kagoshima, Kagoshima-ken, Japan · Recruiting

  • Tokai University Hopital

    Isehara, Kanagawa, Japan · Recruiting

  • Nippon Medical School Musashikosugi Hospital

    Kawasaki, Kanagawa, Japan · Recruiting

  • Kumamoto University Hospital

    Kumamoto, Kumamoto, Japan · Recruiting

  • Japanese Red Cross Kumamoto Hospital

    Kumamoto, Kumamoto, Japan · Not yet recruiting

  • Japanese Red Cross Kyoto Daini Hospital

    Kyoto, Kyoto, Japan · Recruiting

  • University Hospital Kyoto Prefectural University of Medicine

    Kyoto, Kyoto, Japan · Recruiting

  • Nagasaki University Hospital

    Nagasaki, Nagasaki, Japan · Recruiting

  • Kawasaki Medical School Hospital

    Kurashiki, Okayama-ken, Japan · Recruiting

  • Kansai Medical University Hospital

    Hirakata, Osaka, Japan · Recruiting

  • Osaka National Hospital

    Osaka, Osaka, Japan · Recruiting

  • Osaka Keisatsu Hospital

    Osaka, Osaka, Japan · Recruiting

  • Osaka General Medical Center

    Osaka, Osaka, Japan · Recruiting

  • Kindai University Hopital

    Sakai, Osaka, Japan · Recruiting

  • The University of Osaka Hospital

    Suita, Osaka, Japan · Recruiting

  • Saitama Medical University International Medical Center

    Hidaka, Saitama, Japan · Recruiting

  • Japanese Red Cross Saitama Hospital

    Saitama, Saitama, Japan · Recruiting

  • Dokkyo Medical University Hospital

    Mibu, Tochigi, Japan · Recruiting

  • Jichi Medical University Hospital

    Shimotsuke, Tochigi, Japan · Recruiting

  • Tokushima University Hospital

    Tokushima, Tokushima, Japan · Recruiting

  • Tokyo Women's Medical University Adachi Medical Center

    Adachi-ku, Tokyo, Japan · Recruiting

  • Institute of Science Tokyo Hospital

    Bunkyō-Ku, Tokyo, Japan · Recruiting

  • Nippon Medical School Hospital

    Bunkyō-Ku, Tokyo, Japan · Recruiting

  • Showa General Hospital

    Kodaira, Tokyo, Japan · Recruiting

  • Showa Medical University Koto Toyosu Hospital

    Koto-ku, Tokyo, Japan · Not yet recruiting

  • The Jikei University Hspital

    Minato-Ku, Tokyo, Japan · Recruiting

  • Tokyo Saiseikai Central Hospital

    Minato-Ku, Tokyo, Japan · Recruiting

  • Kyorin University Hospital

    Mitaka, Tokyo, Japan · Recruiting

  • Toho University Omori Medical Center

    Ōta-ku, Tokyo, Japan · Not yet recruiting

  • Tokyo Medical University Hospital

    Shinjuku-Ku, Tokyo, Japan · Recruiting

  • Tokyo Women's Medical University Hospital

    Shinjuku-Ku, Tokyo, Japan · Recruiting

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.